Protocols · Growth Hormone
CJC-1295/Ipamorelin Growth Hormone Protocol
GHRH + GHRP Secretagogue Stack | GH Pulse Restoration & Recovery
Typical Dose
100–300 mcg / 100–300 mcg
CJC-1295 + Ipamorelin SC nightly
Route
Subcutaneous
Insulin syringe, abdominal SC
Cycle
12–16 weeks on / 4 off
5 nights on, 2 nights off weekly
Storage
Refrigerate 2–8°C
After reconstitution; lyophilized stable at room temp short-term
Patient version available. Share ?view=patient with patients for the plain-language handout.
Overview
This protocol leverages the synergistic combination of CJC-1295 (a GHRH analog) and Ipamorelin (a selective GHRP/ghrelin mimetic) to restore physiologic growth hormone pulsatility in adults with age-related somatopause, suboptimal IGF-1, or clinical features of GH insufficiency that do not meet criteria for recombinant hGH replacement. The goal is endogenous pulse restoration rather than supraphysiologic GH exposure, preserving the negative feedback loop via somatostatin and minimizing the metabolic disturbances associated with exogenous rhGH.
Target patients typically present with reduced lean mass, slow soft-tissue recovery, decreased sleep quality (particularly slow-wave sleep), declining exercise tolerance, and IGF-1 in the lower quartile for age. The protocol is best suited to adults age 35–65 with intact pituitary function, normal prolactin and cortisol axes, and no active malignancy.
Together, the GHRH + GHRP pairing produces a synergistic GH release substantially greater than either agent alone — exploiting two distinct receptor pathways at the somatotroph while maintaining pulsatile, sleep-entrained secretion patterns.
Key Benefits
Restores endogenous, pulsatile GH release with downstream IGF-1 rise — driving improved sleep depth, lean mass, recovery, and skin/connective tissue quality without the supraphysiologic exposure of rhGH.
Mechanism of Action
CJC-1295 activates pituitary GHRH receptors while Ipamorelin selectively agonizes GHS-R1a (ghrelin receptor), producing a synergistic 2–5× GH pulse that preserves somatostatin feedback and avoids cortisol/prolactin elevation.
Pharmacokinetics
Peak
15–30 min post-injection
Half-life
CJC-1295 ~30 min; Ipamorelin ~2 hr
Cleared
Within ~6–8 hours
Research Indications
GH Optimization & RecoveryEFFECTIVE
Age-related somatopause
Restores pulsatile GH and raises IGF-1 toward upper quartile of age-adjusted range over 6–8 weeks.
Sleep architecture
Deepens slow-wave sleep; often the earliest reported subjective benefit by week 2–4.
Body composition
Typical 1–3 lb lean mass gain by week 8, with reduced visceral adiposity in responders.
Connective tissue recovery
Improved tendon, joint, and post-exercise recovery; supports return-from-injury protocols.
Healthspan EndpointsEMERGING
Skin quality
Anecdotal and observational improvements in skin elasticity and hydration over 8–12 weeks.
Long-term outcomes
No RCTs on the specific CJC/Ipa combination for healthspan or longevity endpoints; use is empirical.
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Induction (Weeks 1–2) | 100/100 mcg | Nightly, 5 on / 2 off | SC |
| Titration (Weeks 3–8) | 200–300/200–300 mcg | Nightly, 5 on / 2 off | SC |
| Maintenance (Weeks 9–12) | 200–300/200–300 mcg | Nightly, 5 on / 2 off | SC |
| Pre-workout (optional) | 100–200/100–200 mcg | 30–60 min pre-training | SC |
| Larger patient / athlete | 300/300 mcg | Nightly or BID | SC (use 20 mg vial) |
Timing · Inject 60–90 minutes after the final meal and immediately before sleep. Carbohydrate or insulin spikes within 60 minutes blunt the GH pulse. Avoid concurrent glucocorticoids near dosing window.
Peptide Interactions
- Tesamorelin— Redundant GHRH axis stimulation; choose one secretagogue strategy.AVOID
- Recombinant hGH— Suppresses endogenous pulsatility; combined use not recommended.AVOID
- Sermorelin— Same GHRH-R pathway as CJC-1295; no added benefit.AVOID
- BPC-157— Complementary tissue repair; commonly stacked for tendon/injury recovery.SYNERGISTIC
- TB-500— Connective tissue and recovery synergy with GH/IGF-1 axis.SYNERGISTIC
- Tirzepatide / Semaglutide— Watch fasting glucose; GH secretagogues mildly oppose insulin sensitivity.MONITOR
- Testosterone (TRT)— Common combined anti-aging protocol; monitor hematocrit and IGF-1 together.SYNERGISTIC
- MK-677 (Ibutamoren)— Overlapping GHS-R1a activity; risk of excessive IGF-1 and edema.AVOID
- GHRP-2 / GHRP-6— Redundant ghrelin agonism; increases cortisol/prolactin risk vs. Ipamorelin alone.AVOID
How to Reconstitute
- 1
Wash hands and prepare a clean surface with alcohol swabs, bacteriostatic water, and the lyophilized blend vial.
- 2
Allow the lyophilized vial to reach room temperature for 5–10 minutes before reconstitution.
- 3
Swab the rubber stoppers of both the bac water vial and the peptide vial with alcohol.
- 4
Draw 2.0 mL of bacteriostatic water into a sterile syringe.
- 5
Inject the bac water slowly down the inner wall of the peptide vial — do not spray directly onto the powder.
- 6
Gently swirl the vial; do NOT shake. Allow the powder to dissolve fully (1–2 minutes).
- 7
Inspect the solution — it should be clear and colorless with no particulates.
- 8
For 10 mg vial: 20 units on an insulin syringe = 100 mcg CJC + 100 mcg Ipa. For 20 mg vial: 20 units = 200 mcg + 200 mcg.
- 9
Label the vial with reconstitution date and store refrigerated at 2–8°C.
- 10
For injection: swab abdominal SC site, pinch skin, insert at 90°, inject slowly, withdraw and apply light pressure.
- 11
Rotate injection sites nightly to minimize lipohypertrophy or erythema.
- 12
Discard reconstituted vial after 30 days or sooner if cloudiness develops.
Quality Indicators
Clear solution after reconstitution
Properly reconstituted blend is clear, colorless, and particulate-free.
COA from 503A/503B pharmacy
Verify identity, purity (>98%), and endotoxin testing on the certificate of analysis.
Slight foaming on swirl
Minor foam dissipates within minutes; persistent foam suggests shaking damage.
Cloudy or discolored solution
Indicates contamination, degradation, or improper reconstitution — discard.
Visible particulates
Do not inject; return to compounding pharmacy for replacement.
What to Expect
Week 1–2: deeper sleep, vivid dreams, transient flushing or head-rush 5–15 min post-injection.
Week 2–4: improved morning recovery, exercise tolerance trending upward, mild appetite increase.
Week 4: IGF-1 typically up 20–40% from baseline on first recheck.
Week 6–8: measurable lean mass gain (1–3 lb), reduced visceral adiposity in responders, improved skin hydration.
Week 8–12: joint and tendon recovery noticeably improved; body composition shift visible on DEXA.
Week 12: IGF-1 should plateau in upper quartile of age-adjusted range — target achieved.
Possible mild fasting glucose rise; monitor at 8–12 weeks.
Some patients report flattening of effect after 12+ weeks, supporting cycling strategy.
Non-responders (<10% IGF-1 rise at 8 weeks) warrant workup for pituitary, sleep, or inflammatory causes.
Side Effects & Safety
- Injection-site erythema, pruritus, or transient welts
- Flushing or head-rush within 5–15 minutes post-injection
- Vivid dreams and transient sleep disturbance in first 1–2 weeks
- Transient water retention and peripheral edema
- Mild arthralgia or carpal-tunnel-like paresthesias (dose-dependent)
- Increased appetite (Ipamorelin component)
- Mild rise in fasting glucose and HOMA-IR
When to Stop & Call Provider
- Persistent or worsening paresthesias / carpal tunnel symptoms
- HbA1c rising above 6.5 or fasting glucose >115 mg/dL
- New or worsening peripheral edema unresponsive to dose reduction
- Any new malignancy diagnosis or suspicious finding
- Vision changes (rule out diabetic retinopathy progression)
- Severe injection-site reaction or systemic hypersensitivity
References
Ipamorelin: selective GH secretagogue without cortisol/prolactin elevation
Early clinical pharmacology demonstrated Ipamorelin as a selective GHS-R1a agonist producing robust GH release without significant effects on ACTH, cortisol, or prolactin — distinguishing it from GHRP-2 and GHRP-6.
CJC-1295 (Mod GRF 1-29) pharmacokinetics and GH release
GHRH(1-29) analog without DAC demonstrates ~30-minute half-life with preserved pulsatile GH release pattern, supporting nightly bedtime dosing aligned with physiologic GH pulse.
GHRH + GHRP combined administration studies
Mechanistic studies show 2–5× greater GH AUC with combined GHRH analog + ghrelin mimetic vs. either agent alone, via complementary cAMP and IP3/Ca2+ pathways on the somatotroph.
Long-term CJC-1295/Ipamorelin outcome data
No long-term RCTs exist for the specific CJC-1295/Ipamorelin combination on body composition, recovery, or healthspan endpoints. Clinical use is empirical, extrapolated from rhGH literature and short-term secretagogue studies.